{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:17:09Z","timestamp":1787894229295,"version":"build-2784847793"},"reference-count":64,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Antimitotic agents are very successful antitumor therapies, but lack tumor selectivity, causing toxicity. Antitumor alkylphospholipids (APLs) selectively accumulate in tumor cells but display low potencies. Hypothesis: Incorporating APL moieties onto antimitotic N-trimethoxyphenyl naphthalene sulfonamides (TMNS) might afford SMDCs with the potency of antimitotics and the tumor selectivity of APLs. Methods: 24 new TMNSs with spacers of different lengths (4 to 9 atoms) and nature (alkanes or ethers) on the sulfonamide nitrogen and capped with phosphorus-containing groups such as diethylphosphonates, phosphonic acids, and hydrogenophosphonate esters of aminoalcohols (diethylaminopropanol, choline, or dimethylaminoethanol) were designed and synthesized. Their antiproliferative effects against several cancer cell lines and their cotreatment with verapamil to assess whether they are substrates of MDR pumps were evaluated. The mechanism of action was studied: cell cycle effects, apoptosis induction, and immunofluorescence microscopy. Computational studies considered binding to tubulin and pharmacokinetics. Results: Diethyl phosphonates and phosphonic acids are antiproliferative in the micromolar to submicromolar range. P-gp inhibitor verapamil renders inactive compounds active, suggesting that efflux, not binding, removes activity. Mechanistic studies agree with an antimitotic action. Proposed binding to tubulin is similar to TMNS, with the phospholipid-like substituent projecting towards the interdimer space. Conclusions: Hybridization of TMNSs with potentially tumor\u2013targeting APLs yields microtubule-disrupting antitumor compounds. However, the modifications assayed turn the compounds into substrates of MDR. These compounds are a proof of concept of the strategy that might succeed if future modifications avoid MDR and might target the compounds towards cancer cells.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091064","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:59:23Z","timestamp":1787741963000},"page":"1064","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small Molecule Drug Conjugate Hybrids of Naphthalene Sulfonamide and Phospholipid Conjugates Are Microtubule-Disrupting Antitumor Agents"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5452-2435","authenticated-orcid":false,"given":"Noelia","family":"Fern\u00e1ndez-Ceballos","sequence":"first","affiliation":[{"name":"Laboratorio de Qu\u00edmica Org\u00e1nica y Farmac\u00e9utica, Departamento de Ciencias Farmac\u00e9uticas, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-2784","authenticated-orcid":false,"given":"Laura","family":"Gallego-Yerga","sequence":"additional","affiliation":[{"name":"Laboratorio de Qu\u00edmica Org\u00e1nica y Farmac\u00e9utica, Departamento de Ciencias Farmac\u00e9uticas, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1433-1612","authenticated-orcid":false,"given":"Rafael","family":"Pel\u00e1ez","sequence":"additional","affiliation":[{"name":"Laboratorio de Qu\u00edmica Org\u00e1nica y Farmac\u00e9utica, Departamento de Ciencias Farmac\u00e9uticas, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Neophytou, C.M. (2025). Recent Advances in Anti-Cancer Drugs. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178446"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"36441","DOI":"10.1039\/D5RA05472A","article-title":"Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015-2025)","volume":"15","author":"Eissa","year":"2025","journal-title":"RSC Adv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00280-023-04562-3","article-title":"Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: Challenges and opportunities","volume":"92","author":"Rudd","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"24759","DOI":"10.1021\/acs.jmedchem.5c01861","article-title":"Small Molecule-Drug Conjugates: An Emerging Drug Design Strategy for Targeted Therapeutics","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1021\/acs.molpharmaceut.3c01049","article-title":"Small Molecule-Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10863-020-09846-4","article-title":"Lipid composition of the cancer cell membrane","volume":"52","author":"Szlasa","year":"2020","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.6b01027","article-title":"Lipid-Drug Conjugate for Enhancing Drug Delivery","volume":"14","author":"Irby","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.jlr.2024.100544","article-title":"Endogenous ether lipids differentially promote tumor aggressiveness by regulating the SK3 channel","volume":"65","author":"Papin","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"240ra275","DOI":"10.1126\/scitranslmed.3007646","article-title":"Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy","volume":"6","author":"Weichert","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115436","DOI":"10.1016\/j.biopha.2023.115436","article-title":"Antitumor activity of alkylphospholipid edelfosine in prostate cancer models and endoplasmic reticulum targeting","volume":"167","author":"Dakir","year":"2023","journal-title":"BioMed Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1021\/acs.langmuir.8b01539","article-title":"Anticancer Agent Edelfosine Exhibits a High Affinity for Cholesterol and Disorganizes Liquid-Ordered Membrane Structures","volume":"34","author":"Ausili","year":"2018","journal-title":"Langmuir"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9724","DOI":"10.1021\/acs.jmedchem.7b01198","article-title":"Amphiphilic Modulation of Glycosylated Antitumor Ether Lipids Results in a Potent Triamino Scaffold against Epithelial Cancer Cell Lines and BT474 Cancer Stem Cells","volume":"60","author":"Idowu","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2016.06.003","article-title":"Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy","volume":"165","author":"Jaffres","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41467-026-68547-5","article-title":"Ether lipids influence cancer cell fate by modulating iron uptake","volume":"17","author":"Mansell","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pinchuk, A.N., Rampy, M.A., Longino, M.A., Durkee, B.Y., Counsell, R.E., and Weichert, J.P. (2023). Effect of Polar Head Group Modifications on the Tumor Retention of Phospholipid Ether Analogs: Role of the Quaternary Nitrogen. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010171"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/jm00129a020","article-title":"Potential tumor or organ-imaging agents. 30. Radioiodinated phospholipid ethers","volume":"32","author":"Meyer","year":"1989","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1021\/acs.jpcb.3c00654","article-title":"Laurdan Discerns Lipid Membrane Hydration and Cholesterol Content","volume":"127","author":"Krok","year":"2023","journal-title":"J. Phys. Chem. B"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1038\/s41598-017-08564-z","article-title":"A multidimensional phasor approach reveals LAURDAN photophysics in NIH-3T3 cell membranes","volume":"7","author":"Malacrida","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"134004","DOI":"10.1088\/1361-6463\/aa5dbc","article-title":"Laurdan and Di-4-ANEPPDHQ probe different properties of the membrane","volume":"50","author":"Amaro","year":"2017","journal-title":"J. Phys. D. Appl. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1002\/mog2.46","article-title":"Microtubule-targeting agents for cancer treatment: Seven binding sites and three strategies","volume":"2","author":"Wang","year":"2023","journal-title":"MedComm\u2014Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/med.21541","article-title":"Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target","volume":"39","author":"Gonzalez","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"108116","DOI":"10.1016\/j.bioorg.2024.108116","article-title":"Dual-targeting inhibitors involving tubulin for the treatment of cancer","volume":"156","author":"Yakkala","year":"2025","journal-title":"Bioorg Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1021\/acs.jmedchem.1c00100","article-title":"Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy","volume":"64","author":"Shuai","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kobanenko, M.K., Tretiakova, D.S., Shchegravina, E.S., Antipova, N.V., Boldyrev, I.A., Fedorov, A.Y., Vodovozova, E.L., and Onishchenko, N.R. (2022). Liposomal Formulation of a PLA2-Sensitive Phospholipid-Allocolchicinoid Conjugate: Stability and Activity Studies In Vitro. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031034"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"116617","DOI":"10.1016\/j.ejmech.2024.116617","article-title":"Promising anti-proliferative indolic benzenesulfonamides alter mechanisms with sulfonamide nitrogen substituents","volume":"275","author":"Hanes","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106282","DOI":"10.1016\/j.bioorg.2022.106282","article-title":"Novel amino analogs of the trimethoxyphenyl ring in potent colchicine site ligands improve solubility by the masked polar group incorporation (MPGI) strategy","volume":"131","author":"Gonzalez","year":"2023","journal-title":"Bioorg Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1080\/14756366.2021.1975277","article-title":"New indolesulfonamide derivatives targeting the colchicine site of tubulin: Synthesis, anti-tumour activity, structure-activity relationships, and molecular modelling","volume":"36","author":"Gonzalez","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14756366.2021.1925265","article-title":"Methoxy and bromo scans on N-(5-methoxyphenyl) methoxybenzenesulphonamides reveal potent cytotoxic compounds, especially against the human breast adenocarcinoma MCF7 cell line","volume":"36","author":"Gonzalez","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gonzalez, M., Ovejero-Sanchez, M., Vicente-Blazquez, A., Alvarez, R., Herrero, A.B., Medarde, M., Gonzalez-Sarmiento, R., and Pelaez, R. (2021). Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041907"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cmdc.201100361","article-title":"The tubulin colchicine domain: A molecular modeling perspective","volume":"7","author":"Massarotti","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2174\/1568026614666141130092637","article-title":"New ligands of the tubulin colchicine site based on X-ray structures","volume":"14","author":"Alvarez","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Marin, M., Fuentes-Martin, R., Sanchez, B., Gallego-Yerga, L., and Pelaez, R. (2026). Antimitotic Naphthalene Sulfonamides Are Potent Antitumor Agents Acting Differently from Colchicine. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18060733"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0040-4039(01)92575-4","article-title":"The facile dealkylation of phosphonic acid dialkyl esters by bromotrimethylsilane","volume":"18","author":"McKenna","year":"1977","journal-title":"Tetrahedron Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/slct.201702149","article-title":"Synthesis of O-Alkyl Alkylphosphonates via Hydrazine Mediated Partial Dealkylation of Phosphonate Diesters","volume":"3","author":"Pardasani","year":"2018","journal-title":"ChemistrySelect"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113656","DOI":"10.1016\/j.ejmech.2021.113656","article-title":"Anticancer properties of indole derivatives as IsoCombretastatin A-4 analogues","volume":"223","author":"Pecnard","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejmech.2017.02.049","article-title":"Beta-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells","volume":"130","author":"Malebari","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mialhe, A., Pais de Barros, J.-P., Hermetet, F., Limagne, E., Ghiringhelli, F., Aires, V., and Delmas, D. (2026). Phosphatidylcholine and CHPT1 as Central Drivers of Chemoresistance in Colorectal Cancer: Lipidomic and Functional Insights. Cells, 15.","DOI":"10.3390\/cells15050439"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ezzo, M., and Etienne-Manneville, S. (2025). Microtubule-Targeting Agents: Advances in Tubulin Binding and Small Molecule Therapy for Gliomas and Neurodegenerative Diseases. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157652"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gallego-Yerga, L., Chiliquinga, A.J., and Pelaez, R. (2023). Novel Tetrazole Derivatives Targeting Tubulin Endowed with Antiproliferative Activity against Glioblastoma Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241311093"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/bse0500161","article-title":"The P-glycoprotein multidrug transporter","volume":"50","author":"Sharom","year":"2011","journal-title":"Essays Biochem"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4155\/fmc.15.36","article-title":"P-glycoprotein and membrane roles in multidrug resistance","volume":"7","author":"Ferreira","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_44","first-page":"1967","article-title":"Overcoming of Vincristine Resistance in p388 Leukemia in Vivo and in Vitro Through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil","volume":"41","author":"Tsuruo","year":"1981","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1158\/0008-5472.CAN-04-0143","article-title":"Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1","volume":"64","author":"Trompier","year":"2004","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"31542","DOI":"10.1074\/jbc.M703964200","article-title":"(R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1","volume":"282","author":"Perrotton","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_47","first-page":"5.7.1\u20135.7.18","article-title":"Analysis of cellular DNA content by flow cytometry","volume":"5","author":"Darzynkiewicz","year":"2004","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_48","first-page":"2597","article-title":"Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death","volume":"50","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1016\/j.csbj.2021.07.039","article-title":"Application of ensemble pharmacophore-based virtual screening to the discovery of novel antimitotic tubulin inhibitors","volume":"19","author":"Ochoa","year":"2021","journal-title":"Comput Struct. Biotechnol. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1021\/jm3015603","article-title":"Endowing indole-based tubulin inhibitors with an anchor for derivatization: Highly potent 3-substituted indolephenstatins and indoleisocombretastatins","volume":"56","author":"Alvarez","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein-ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"Forli","year":"2016","journal-title":"Nat. Protoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/ci800298z","article-title":"Empirical scoring functions for advanced protein-ligand docking with PLANTS","volume":"49","author":"Korb","year":"2009","journal-title":"J. Chem. Inf. Model"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","article-title":"Physiochemical drug properties associated with in vivo toxicological outcomes","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg Med. Chem. Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/bioinformatics\/btv087","article-title":"SOMP: Web server for in silico prediction of sites of metabolism for drug-like compounds","volume":"31","author":"Rudik","year":"2015","journal-title":"Bioinformatics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1021\/acs.jcim.9b00376","article-title":"FAME 3: Predicting the Sites of Metabolism in Synthetic Compounds and Natural Products for Phase 1 and Phase 2 Metabolic Enzymes","volume":"59","author":"Sicho","year":"2019","journal-title":"J. Chem. Inf. Model"},{"key":"ref_58","unstructured":"(2024, October 18). ChemAxon Marvin, Available online: https:\/\/chemaxon.com\/products\/marvin\/download."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-1-4939-6952-4_20","article-title":"AutoDock and AutoDockTools for Protein-Ligand Docking: Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1(BACE1) as a Case Study","volume":"1598","author":"Khalil","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_60","unstructured":"Berthold, M.R.C., Dill, N., and Gabriel, F. (2006, January 8\u201310). KNIME: The Konstanz Information Miner. Proceedings of the Studies in Classification, Data Analysis, and Knowledge Organization, Berlin, Germany."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1093\/bioinformatics\/btaa018","article-title":"LigRMSD: A web server for automatic structure matching and RMSD calculations among identical and similar compounds in protein-ligand docking","volume":"36","author":"Caballero","year":"2020","journal-title":"Bioinformatics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput Chem."},{"key":"ref_63","unstructured":"(2024, October 18). OpenEye Scientific. Available online: https:\/\/www.eyesopen.com."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/bioinformatics\/btw677","article-title":"JADOPPT: Java based AutoDock preparing and processing tool","volume":"33","author":"Pelaez","year":"2017","journal-title":"Bioinformatics"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:27:30Z","timestamp":1787891250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":64,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091064"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091064","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}